f Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Future Directions

References

1. WangR. ChenY. ShaoX. Burden of skin cancer in older adults from 1990 to 2021 and modelled projection to 2050.JAMA Dermatol.2025161771572210.1001/jamadermatol.2025.1276 40397469
   [Google Scholar]
2. ParkerE.R. The influence of climate change on skin cancer incidence – A review of the evidence.Int. J. Womens Dermatol.202171172710.1016/j.ijwd.2020.07.003 33537393
   [Google Scholar]
3. HussainS. MubeenI. UllahN. Modern diagnostic imaging technique applications and risk factors in the medical field: A review.BioMed Res. Int.202220221516497010.1155/2022/5164970 35707373
   [Google Scholar]
4. TawbiH.A. SchadendorfD. LipsonE.J. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma.N. Engl. J. Med.20223861243410.1056/NEJMoa2109970 34986285
   [Google Scholar]
5. WolchokJ.D. Chiarion-SileniV. RutkowskiP. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma.N. Engl. J. Med.20253921112210.1056/NEJMoa2407417 39282897
   [Google Scholar]
6. GrossN.D. MillerD.M. KhushalaniN.I. Neoadjuvant cemiplimab for stage ii to iv cutaneous squamous-cell carcinoma.N. Engl. J. Med.2022387171557156810.1056/NEJMoa2209813 36094839
   [Google Scholar]
7. GrobJ.J. GonzalezR. Basset-SeguinN. Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase ii trial (KEYNOTE-629).J. Clin. Oncol.202038252916292510.1200/JCO.19.03054 32673170
   [Google Scholar]
8. MigdenM.R. RischinD. SchmultsC.D. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma.N. Engl. J. Med.2018379434135110.1056/NEJMoa1805131 29863979
   [Google Scholar]
9. RischinD. PorcedduS. DayF. Adjuvant cemiplimab or placebo in high-risk cutaneous squamous-cell carcinoma.N. Engl. J. Med.2025393877478510.1056/NEJMoa2502449 40454639
   [Google Scholar]
10. AbobakerM. GovenderM. ChoonaraY.E. Non-surgical synergistic interventions for the treatment of skin cancer.Curr. Pharm. Des.202632424526010.2174/0113816128298264240530061039 38910485
    [Google Scholar]
11. ShresthaS. CookC.M. ParekhJ. MatteiJ. A review on melanoma brain metastases.Curr. Pharm. Des.202632426126610.2174/0113816128340742250118150157 40017253
    [Google Scholar]
12. EscobarG.F. PauvelsL.S.P. BakosR.M. Dermoscopic aspects of cutaneous melanoma and non-melanoma skin cancer.Curr. Pharm. Des.202632427628410.2174/0113816128341374250310055950
    [Google Scholar]
13. KreidiehF. WongM.K. New standards in the treatment of advanced metastatic melanoma: Immunotherapy and BRAF-targeted therapies as emerging paradigms.Curr. Pharm. Des.202632428530010.2174/0113816128341628250519093548 40442907
    [Google Scholar]
14. ChedidM. Surgical excision margins in skin melanomas with breslow thickness greater than 2 mm: A systematic review and meta-analysis.Curr. Pharm. Des.202632430130510.2174/0113816128341363250225095747 40108923
    [Google Scholar]
15. ChakrabortyR. GohainR.B. TalukdarP. Pre-clinical safety study of cold atmospheric plasma (CAP) produced by an inbuilt CAP device and ROS mediated apoptotic activity in human skin melanoma cells.Curr. Pharm. Des.202632430631910.2174/0113816128335012250122221541 40070328
    [Google Scholar]